(Q37687867)

22 August 2017

1 reference

title

Top-down therapy for IBD: rationale and requisite evidence (English)

1 reference

22 August 2017

Geert R D'Haens

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

86-92

1 reference

THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Inflammatory bowel disease: cause and immunobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Inflammatory bowel disease: clinical aspects and established and evolving therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Disease activity courses in a regional cohort of Crohn's disease patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Intestinal cancer risk and mortality in patients with Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Course of ulcerative colitis: analysis of changes in disease activity over years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

The European consensus on ulcerative colitis: new horizons?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Colorectal cancer prevention in ulcerative colitis: a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Intensive intravenous treatment of ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

A controlled double blind study of azathioprine in the management of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Infliximab prevents Crohn's disease recurrence after ileal resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Infliximab maintenance therapy for fistulizing Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Adalimumab for the treatment of fistulas in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

European evidence based consensus on the diagnosis and management of Crohn's disease: special situations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Early versus late surgery for ileo-caecal Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Review article: thiopurines in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Risks and benefits of infliximab for the treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Complications of biological therapy for inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Risks and benefits of biologic therapy for inflammatory bowel diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Predictors of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Predictors of severe Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Effect of cigarette smoking on recurrence of Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Clinical pattern of corticosteroid dependent Crohn's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Genetic risk profiling and prediction of disease course in Crohn's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Safety profile of IBD: lymphoma risks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.222

Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies

31 March 2020

1 reference

12 December 2020

Predictability of the postoperative course of Crohn's disease

1 reference

12 December 2020

Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease

1 reference

12 December 2020

Clinical features and natural history of Crohn's disease

1 reference

12 December 2020

10.1038/NRGASTRO.2009.222

Identifiers

DOI

1 reference

22 August 2017

1 reference